Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

Share Price is delayed by 15 minutes
Get Live Data
2,209.00    19.00 (0.87%)
Bid:
2,212.00
Ask:
2,214.00
Spread: 2.00 (0.09%)
Market Cap: £22.41b
III Live PriceLast checked at - London Stock Exchange

Intraday 3i Group Share Chart

Section 430 (2B) Companies Act 2006 Statement

1 Jul 2022 11:14

RNS Number : 0261R
3i Group PLC
01 July 2022
 

Statement under section 430(2B) Companies Act 2006 in relation to Mrs Julia Wilson

 

Further to the announcement made on 11 November 2021, Julia Wilson, retired as Group Finance Director and as an Executive Director of 3i Group plc (the "Company") at the conclusion of the Company's Annual General Meeting ("AGM") on 30 June 2022. 

 

The following information is provided in accordance with section 430(2B) of the Companies Act 2006:

 

Mrs Wilson's remuneration terms will be in line with her existing service agreement and the Company's Directors' Remuneration Policy approved by shareholders at the AGM in 2020. Details of these remuneration arrangements are set out in the 2022 Directors' Remuneration Report and further detail will be disclosed in the 2023 Directors' Remuneration Report where required.

 

Mrs Wilson will remain employed by the Company until 30 September 2022. This is intended to ensure support and continuity for the new Executive Directors and allow for an orderly transition.

 

Mrs Wilson will not receive any payment for loss of office.

 

Salary, Pension and Benefits

 

Mrs Wilson will continue to receive her salary, pension allowance and benefits in line with her service agreement up to and including 30 September 2022 when her employment will cease. As set out in the 2022 Directors' Remuneration Report, Mrs Wilson's salary will be £504,176 p.a. for the period from 1 July 2022 until her employment ends on 30 September 2022.

 

Mrs Wilson's benefits include a car allowance, provision of health insurance and, the value of the matching share awards under the 3i Group Share Incentive Plan in which Mrs Wilson participates. Details of these benefits are summarised in the 2022 Directors' Remuneration Report.

 

Mrs Wilson will not be eligible to receive an annual bonus for the financial year to 31 March 2023.

 

Incentives

 

On leaving employment Mrs Wilson will be treated as a good leaver for purposes of the Directors' Remuneration Policy.

 

3i Group Share Incentive Plan

 

Outstanding shares held under the 3i Group Share Incentive Plan on leaving employment will be treated in accordance with the applicable rules.  Shares will be released to her subject to any deductions required under PAYE.

 

Balance in the Share Incentive Plan on 30 June 2022.

 

Partnership Shares

Matching Shares

Dividend Shares

Total

5,432

10,864

5,695

21,991

 

 

 

 

 

Deferred Bonus Plan

 

Mrs Wilson's unreleased awards under the 3i Deferred Bonus Plan and the 3i Group Deferred Bonus Plan 2020 over a total of 125,219 shares will be retained and will (subject to the rules of the relevant Plan) be released on their original release dates. The awards remain subject to malus and clawback provisions and Mrs Wilson will continue to receive dividends on the shares comprised in these awards pending their release.

 

Mrs Wilson is not be entitled to receive any further awards under the 3i Group Deferred Bonus Plan.

 

Long-term incentive awards

 

Outstanding long-term incentive awards under the 3i Group Discretionary Share Plan and the 3i Group Discretionary Share Plan 2020 will (subject where applicable to satisfaction of outstanding performance conditions) be retained and will be released in line with the original release dates.

 

Awards made in 2020 and 2021 will be pro-rated for the proportion of the three year performance period for which Mrs Wilson remains in employment.

 

As the awards made in 2018 and 2019 have already completed their three-year performance periods and have vested (with performance outcomes resulting in 70.63% performance vesting and 100% performance vesting respectively), these vested awards (to the extent they remain unreleased) will not be time pro-rated and will continue to be released on their scheduled release dates, subject to the rules of the relevant Plan.

 

The awards, totalling 224,970 shares, will remain subject to malus and clawback provisions and will accumulate dividend equivalents and interest until they are released.

 

Shareholding requirement

 

Mrs Wilson will be expected to maintain a shareholding in the Company for two years post cessation of employment at 200% of her salary as at 30 September 2022.

 

In accordance with section 430 (2B) of the Companies Act 2006, a copy of this statement is available on the Company's website at www.3i.com.

 

 

-Ends-

 

For further information, contact:

Kathryn van der Kroft 020 7975 3021

Communications Director

 

Silvia Santoro 020 7975 3258

Investor Relations Director

 

Notes to Editors:

 

About 3i

 

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America. For further information, please visit: www.3i.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURMZGGNGMFGZZM
Date   Source Headline
5th Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20264:24 pmRNSDirector/PDMR Shareholding
2nd Jun 20263:37 pmRNSDirector/PDMR Shareholding - Amendment
1st Jun 20264:28 pmRNSDirector/PDMR Shareholding
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:42 pmRNSTotal Voting Rights
29th May 20265:38 pmRNSAdmission to Trading
27th May 202610:42 amRNSNotice of AGM
26th May 20267:00 amRNSTransaction in Own Shares
22nd May 202612:29 pmRNSDirector/PDMR Shareholding
21st May 20267:40 amRNSDoc re. 2026 Annual Report and Accounts
19th May 20262:28 pmRNSDirector/PDMR Shareholding
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202610:24 amRNSDirector/PDMR Shareholding
14th May 202610:41 amRNSHolding(s) in Company
14th May 20267:02 amRNSCommencement of Share Buyback Programme
14th May 20267:00 amRNSResults for the year to 31 March 2026
1st May 202612:00 pmRNSDirector/PDMR Shareholding
30th Apr 20263:34 pmRNSTotal Voting Rights
30th Apr 20263:31 pmRNSAdmission to Trading
7th Apr 202612:33 pmRNSHolding(s) in Company
1st Apr 20269:53 amRNSPortfolio Update
1st Apr 20269:36 amRNSDirector/PDMR Shareholding
31st Mar 20262:30 pmRNSTotal Voting Rights
31st Mar 20262:29 pmRNSAdmission to Trading
31st Mar 202611:37 amRNSDirector/PDMR Shareholding
30th Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:07 pmRNSAdmission to Trading
26th Mar 20267:00 amRNSAction Capital Markets Seminar & portfolio update
23rd Mar 202612:11 pmRNSHolding(s) in Company
2nd Mar 202612:18 pmRNSDirector/PDMR Shareholding
27th Feb 20264:00 pmRNSTotal Voting Rights
3rd Feb 202610:20 amRNSHolding(s) in Company
3rd Feb 202610:17 amRNSDirector Declaration
30th Jan 20262:24 pmRNSDirector/PDMR Shareholding
30th Jan 20261:47 pmRNSTotal Voting Rights
29th Jan 202612:19 pmRNSDirector/PDMR Shareholding
29th Jan 20267:00 amRNSFY2026 Q3 performance update
7th Jan 20262:06 pmRNSDirector/PDMR Shareholding
6th Jan 20261:53 pmRNSTotal Voting Rights
2nd Jan 202611:06 amRNSPortfolio Update
9th Dec 20251:11 pmRNSBlock listing Interim Review
4th Dec 20252:12 pmRNSDirector/PDMR Shareholding
1st Dec 20251:25 pmRNSDirector/PDMR Shareholding
28th Nov 20254:24 pmRNSTotal Voting Rights
20th Nov 20259:59 amRNSDirector/PDMR Shareholding
18th Nov 20252:23 pmRNSDirector/PDMR Shareholding
17th Nov 202512:50 pmRNSDirector/PDMR Shareholding
17th Nov 202512:48 pmRNSDirector/PDMR Shareholding
14th Nov 20254:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.